A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. (Q34030597)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. |
scientific article |
Statements
1 reference
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. (English)
1 reference
Eric J Lawitz
1 reference
Daniel Gruener
1 reference
John M Hill
1 reference
Thomas Marbury
1 reference
Lisa Moorehead
1 reference
Anita Mathias
1 reference
Guofeng Cheng
1 reference
John O Link
1 reference
Kelly A Wong
1 reference
Hongmei Mo
1 reference
John G McHutchison
1 reference
Diana M Brainard
1 reference
5 February 2012
1 reference
1 reference
Identifiers
1 reference